Fulltext

Treatment of travellers' diarrhoea with fleroxacin: a case study

Steffen, R. ; Jori, J. ; DuPont, H. L. ; Mathewson, J. J. ; Stürchler, D.

In: Journal of Antimicrobial Chemotherapy, 1993, vol. 31, no. 5, p. 767-776

Ajouter à la liste personnelle
    Titre
    • Treatment of travellers' diarrhoea with fleroxacin: a case study
    Auteur
    • Steffen, R.. Institute of Social and Preventive Medicine, University of Zurich Sumatrastrasse 30, CH-8006 Zurich
    • Jori, J.. Institute of Social and Preventive Medicine, University of Zurich Sumatrastrasse 30, CH-8006 Zurich
    • DuPont, H. L.. Program in Infectious Diseases and Clinical Microbiology, University of Texas P.O. Box 20708, Houston, Texas 77225, USA
    • Mathewson, J. J.. Program in Infectious Diseases and Clinical Microbiology, University of Texas P.O. Box 20708, Houston, Texas 77225, USA
    • Stürchler, D.. F. Hoffmann-La Roche Ltd CH-4002 Basle, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Journal of Antimicrobial Chemotherapy, 1993, vol. 31, no. 5, p. 767-776. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:297918
    Summary
    A double-blind, randomized, placebo-controlled trial was conducted to evaluate the efficacy and safety of fleroxacin for one or two days as treatment for patients with travellers' diarrhoea. A total of 195 patients who were suffering with acute diarrhoea of less than six days' duration were enrolled. One hundred and fifty-one patients, of whom 49 received placebo, 54 received fleroxacin 400 mg for one day and 48 received fleroxacin 400 mg for two days, were included in the analysis of efficacy. The results showed that fleroxacin was significantly superior to placebo, but that there was no significant difference in terms of efficacy between the one- and two-day regimens. Adverse events, particularly minor neuropsychiatric disturbances such as headache and insomnia, were significantly more common amongst patients receiving active treatment. In conclusion, a single dose of fleroxacin 400 mg could be recommended as self-treatment for visitors to high-risk countries who develop travellers' diarrhoea